InsidersTradesSigma
Follow the Imugene Limited stock price and the full management transaction log of the company, a listed equity based in Australia. Shares trade on AU AU, under the supervision of ASX. Operating in the Health Care sector, Imugene Limited has logged 2 insider filings. Market capitalisation: €42.5m. The latest transaction was disclosed on 7 July 2026 (Other). Among the most active insiders: Unknown. Every trade is openly available.
Analysts rate Imugene Limited Strong Buy (bullish), based on 3 analysts. Average price target: A$0.31.
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
Imugene Limited is a biopharmaceutical company focused on developing immunotherapeutic treatments for cancer. It is listed on the Australian Securities Exchange under the ticker IMU.